Advanced Search
Display options
Filter resources
Text Availability
Article type
Publication date
Species
Language
Sex
Age
Showing 1 to 12 of 448 entries
Sorted by: Best Match Show Resources per page
… : Current address of Dr. Karin M. Kirschner is at Johannes-Müller Institut fu̇r Physiologie, Charité-Universitätsmedizin Berlin, Campus Charité-Mitte, Tucholskystrasse …

science campus

[No authors listed]
GSID: 1s73hdO2Rq8J
KM Kirschner, K Baltensperger - Molecular cancer research, 2003 - AACR

Chronic myeloid leukemia is characterized by the Philadelphia chromosome translocation that causes expression of Bcr-Abl, a deregulated tyrosine kinase. Imatinib mesylate (STI571, Gleevec), a therapeutically used inhibitor of Bcr-Abl, causes apoptosis of Bcr-Abl-positive cells…

Cite
Kirschner, K. M., & Baltensperger, K. (2003). Erythropoietin Promotes Resistance Against the Abl Tyrosine Kinase Inhibitor Imatinib (STI571) in K562 Human Leukemia Cells11Swiss National Science Foundation grant 31-059124 and Swiss Cancer League grant SKL 778-2-1999. Note: Current address of Dr. Karin M. Kirschner is at Johannes-Müller Institut fu̇r Physiologie, Charité-Universitätsmedizin Berlin, Campus Charité-Mitte, Tucholskystrasse 2, 10117 Berlin, Germany. Molecular cancer research, 1(13), 970-980.
Kirschner, Karin M., and Kurt Baltensperger. "Erythropoietin Promotes Resistance Against the Abl Tyrosine Kinase Inhibitor Imatinib (STI571) in K562 Human Leukemia Cells11Swiss National Science Foundation grant 31-059124 and Swiss Cancer League grant SKL 778-2-1999. Note: Current address of Dr. Karin M. Kirschner is at Johannes-Müller Institut fu̇r Physiologie, Charité-Universitätsmedizin Berlin, Campus Charité-Mitte, Tucholskystrasse 2, 10117 Berlin, Germany." Molecular cancer research 1.13 (2003): 970-980.
Copy Download .nbib Format: MLA
Gastrointestinal stromal tumor with an unusual presentation as an enlarged prostate gland: a case report and review of the literature.

Journal of gastrointestinal oncology

Reinke DA, Deisch JK, Reinke DD.
PMID: 27034816
J Gastrointest Oncol. 2016 Apr;7:S71-4. doi: 10.3978/j.issn.2078-6891.2015.023.

We report a case of a 78-year-old male who presented with urinary retention, constipation and an enlarged prostate gland. A transurethral resection of the prostate (TURP) was performed. Pathologic examination revealed a hypercellular-spindled neoplasm with frequent mitoses, nuclear pleomorphism,...

Cite
Reinke DA, Deisch JK, Reinke DD. Gastrointestinal stromal tumor with an unusual presentation as an enlarged prostate gland: a case report and review of the literature. J Gastrointest Oncol. 2016;7:S71-4doi: 10.3978/j.issn.2078-6891.2015.023.
Reinke, D. A., Deisch, J. K., & Reinke, D. D. (2016). Gastrointestinal stromal tumor with an unusual presentation as an enlarged prostate gland: a case report and review of the literature. Journal of gastrointestinal oncology, 7S71-4. https://doi.org/10.3978/j.issn.2078-6891.2015.023
Reinke, Dennis Aaron, et al. "Gastrointestinal stromal tumor with an unusual presentation as an enlarged prostate gland: a case report and review of the literature." Journal of gastrointestinal oncology vol. 7 (2016): S71-4. doi: https://doi.org/10.3978/j.issn.2078-6891.2015.023
Reinke DA, Deisch JK, Reinke DD. Gastrointestinal stromal tumor with an unusual presentation as an enlarged prostate gland: a case report and review of the literature. J Gastrointest Oncol. 2016 Apr;7:S71-4. doi: 10.3978/j.issn.2078-6891.2015.023. PMID: 27034816; PMCID: PMC4783617.
Copy Download .nbib Format: NLM
Acute diffuse peritonitis due to spontaneous rupture of a primary gastrointestinal stromal tumor of the jejunum: A case report.

International journal of surgery case reports

Sato K, Tazawa H, Fujisaki S, Fukuhara S, Imaoka K, Hirata Y, Takahashi M, Fukuda S, Kuga Y, Nishida T, Sakimoto H.
PMID: 28888914
Int J Surg Case Rep. 2017;39:288-292. doi: 10.1016/j.ijscr.2017.08.041. Epub 2017 Aug 23.

INTRODUCTION: Gastrointestinal stromal tumors (GISTs) are the most common mesenchymal tumors of the gastrointestinal tract. Overt peritonitis caused by GIST rupture is very uncommon. Three types of GIST rupture have been described: closed perforation due to abscess (abscess type),...

Cite
Sato K, Tazawa H, Fujisaki S, et al. Acute diffuse peritonitis due to spontaneous rupture of a primary gastrointestinal stromal tumor of the jejunum: A case report. Int J Surg Case Rep. 2017;39:288-292doi: 10.1016/j.ijscr.2017.08.041.
Sato, K., Tazawa, H., Fujisaki, S., Fukuhara, S., Imaoka, K., Hirata, Y., Takahashi, M., Fukuda, S., Kuga, Y., Nishida, T., & Sakimoto, H. (2017). Acute diffuse peritonitis due to spontaneous rupture of a primary gastrointestinal stromal tumor of the jejunum: A case report. International journal of surgery case reports, 39288-292. https://doi.org/10.1016/j.ijscr.2017.08.041
Sato, Koki, et al. "Acute diffuse peritonitis due to spontaneous rupture of a primary gastrointestinal stromal tumor of the jejunum: A case report." International journal of surgery case reports vol. 39 (2017): 288-292. doi: https://doi.org/10.1016/j.ijscr.2017.08.041
Sato K, Tazawa H, Fujisaki S, Fukuhara S, Imaoka K, Hirata Y, Takahashi M, Fukuda S, Kuga Y, Nishida T, Sakimoto H. Acute diffuse peritonitis due to spontaneous rupture of a primary gastrointestinal stromal tumor of the jejunum: A case report. Int J Surg Case Rep. 2017;39:288-292. doi: 10.1016/j.ijscr.2017.08.041. Epub 2017 Aug 23. PMID: 28888914; PMCID: PMC5596258.
Copy Download .nbib Format: NLM
Partial response to imatinib treatment in a patient with unresectable gastrointestinal stromal tumor: A case report and mini literature review.

Experimental and therapeutic medicine

Wu X, Feng L, Liu Q, Xia D, Xu L.
PMID: 27698727
Exp Ther Med. 2016 Oct;12(4):2297-2301. doi: 10.3892/etm.2016.3614. Epub 2016 Aug 23.

The aim of the present study was to evaluate the efficacy and safety of imatinib mesylate in unresectable gastrointestinal stromal tumor (GIST) and to discuss its therapeutic regimen. A patient with unresectable GIST is described, and several key clinical...

Cite
Wu X, Feng L, Liu Q, et al. Partial response to imatinib treatment in a patient with unresectable gastrointestinal stromal tumor: A case report and mini literature review. Exp Ther Med. 2016;12(4):2297-2301doi: 10.3892/etm.2016.3614.
Wu, X., Feng, L., Liu, Q., Xia, D., & Xu, L. (2016). Partial response to imatinib treatment in a patient with unresectable gastrointestinal stromal tumor: A case report and mini literature review. Experimental and therapeutic medicine, 12(4), 2297-2301. https://doi.org/10.3892/etm.2016.3614
Wu, Xiaolong, et al. "Partial response to imatinib treatment in a patient with unresectable gastrointestinal stromal tumor: A case report and mini literature review." Experimental and therapeutic medicine vol. 12,4 (2016): 2297-2301. doi: https://doi.org/10.3892/etm.2016.3614
Wu X, Feng L, Liu Q, Xia D, Xu L. Partial response to imatinib treatment in a patient with unresectable gastrointestinal stromal tumor: A case report and mini literature review. Exp Ther Med. 2016 Oct;12(4):2297-2301. doi: 10.3892/etm.2016.3614. Epub 2016 Aug 23. PMID: 27698727; PMCID: PMC5038182.
Copy Download .nbib Format: NLM
Exacerbation of Psoriasis after Imatinib Mesylate Treatment.

Annals of dermatology

Shim JH, Oh SH, Jun JY, Kim JH, Park HY, Park JH, Lee DY.
PMID: 27274651
Ann Dermatol. 2016 Jun;28(3):409-11. doi: 10.5021/ad.2016.28.3.409. Epub 2016 May 25.

No abstract available.

Cite
Shim JH, Oh SH, Jun JY, et al. Exacerbation of Psoriasis after Imatinib Mesylate Treatment. Ann Dermatol. 2016;28(3):409-11doi: 10.5021/ad.2016.28.3.409.
Shim, J. H., Oh, S. H., Jun, J. Y., Kim, J. H., Park, H. Y., Park, J. H., & Lee, D. Y. (2016). Exacerbation of Psoriasis after Imatinib Mesylate Treatment. Annals of dermatology, 28(3), 409-11. https://doi.org/10.5021/ad.2016.28.3.409
Shim, Joon Ho, et al. "Exacerbation of Psoriasis after Imatinib Mesylate Treatment." Annals of dermatology vol. 28,3 (2016): 409-11. doi: https://doi.org/10.5021/ad.2016.28.3.409
Shim JH, Oh SH, Jun JY, Kim JH, Park HY, Park JH, Lee DY. Exacerbation of Psoriasis after Imatinib Mesylate Treatment. Ann Dermatol. 2016 Jun;28(3):409-11. doi: 10.5021/ad.2016.28.3.409. Epub 2016 May 25. PMID: 27274651; PMCID: PMC4884729.
Copy Download .nbib Format: NLM
Extra-abdominal fibromatosis: Clinical and therapeutic considerations based on an illustrative case.

Oncology letters

Fornaro R, Caratto E, Caratto M, Salerno A, Sarocchi F, Minetti G, Frascio M, Murialdo R, Taviani M.
PMID: 26722296
Oncol Lett. 2015 Nov;10(5):3103-3106. doi: 10.3892/ol.2015.3684. Epub 2015 Sep 08.

Extra-abdominal fibromatosis is a rare, benign disease that is characterized by a local but not metastatic invasivity. In particular, desmoid tumors of the chest wall represent only 10-20% of all deep fibromatoses. The disease occurs more often in females...

Cite
Fornaro R, Caratto E, Caratto M, et al. Extra-abdominal fibromatosis: Clinical and therapeutic considerations based on an illustrative case. Oncol Lett. 2015;10(5):3103-3106doi: 10.3892/ol.2015.3684.
Fornaro, R., Caratto, E., Caratto, M., Salerno, A., Sarocchi, F., Minetti, G., Frascio, M., Murialdo, R., & Taviani, M. (2015). Extra-abdominal fibromatosis: Clinical and therapeutic considerations based on an illustrative case. Oncology letters, 10(5), 3103-3106. https://doi.org/10.3892/ol.2015.3684
Fornaro, Rosario, et al. "Extra-abdominal fibromatosis: Clinical and therapeutic considerations based on an illustrative case." Oncology letters vol. 10,5 (2015): 3103-3106. doi: https://doi.org/10.3892/ol.2015.3684
Fornaro R, Caratto E, Caratto M, Salerno A, Sarocchi F, Minetti G, Frascio M, Murialdo R, Taviani M. Extra-abdominal fibromatosis: Clinical and therapeutic considerations based on an illustrative case. Oncol Lett. 2015 Nov;10(5):3103-3106. doi: 10.3892/ol.2015.3684. Epub 2015 Sep 08. PMID: 26722296; PMCID: PMC4665811.
Copy Download .nbib Format: NLM
Hyperdiploidy associated with T315I mutation in BCR-ABL kinase domain in an accelerated phase-chronic myeloid leukemia case.

Molecular cytogenetics

Al-Achkar W, Moassass F, Ikhtiar A, Liehr T, Othman MA, Wafa A.
PMID: 25621010
Mol Cytogenet. 2014 Nov 29;7(1):89. doi: 10.1186/s13039-014-0089-0. eCollection 2014.

BACKGROUND: Chronic myeloid leukemia (CML) is genetically characterized by the occurrence of a reciprocal translocation t(9;22)(q34;q11), resulting in a BCR/ABL gene fusion on the derivative chromosome 22, i.e. the Philadelphia (Ph) chromosome. During CML progression 60-80% of the cases...

Cite
Al-Achkar W, Moassass F, Ikhtiar A, et al. Hyperdiploidy associated with T315I mutation in BCR-ABL kinase domain in an accelerated phase-chronic myeloid leukemia case. Mol Cytogenet. 2014;7(1):89doi: 10.1186/s13039-014-0089-0.
Al-Achkar, W., Moassass, F., Ikhtiar, A., Liehr, T., Othman, M. A., & Wafa, A. (2014). Hyperdiploidy associated with T315I mutation in BCR-ABL kinase domain in an accelerated phase-chronic myeloid leukemia case. Molecular cytogenetics, 7(1), 89. https://doi.org/10.1186/s13039-014-0089-0
Al-Achkar, Walid, et al. "Hyperdiploidy associated with T315I mutation in BCR-ABL kinase domain in an accelerated phase-chronic myeloid leukemia case." Molecular cytogenetics vol. 7,1 (2014): 89. doi: https://doi.org/10.1186/s13039-014-0089-0
Al-Achkar W, Moassass F, Ikhtiar A, Liehr T, Othman MA, Wafa A. Hyperdiploidy associated with T315I mutation in BCR-ABL kinase domain in an accelerated phase-chronic myeloid leukemia case. Mol Cytogenet. 2014 Nov 29;7(1):89. doi: 10.1186/s13039-014-0089-0. eCollection 2014. PMID: 25621010; PMCID: PMC4305221.
Copy Download .nbib Format: NLM
Subdural hematoma during therapy of gastro-intestinal stromal tumor (GIST) with Imatinib mesylate.

The Gulf journal of oncology

Feki J, Marrekchi G, Boudawara T, Rekik N, Maatouq S, Boudawara Z, Frikha M.
PMID: 25682460
Gulf J Oncolog. 2015 Jan;1(17):92-5.

Imatinib mesylate is a widely used tyrosine-kinase inhibitor (TKI) in chronic myeloid leukemia (CML) treatment. Imatinib has contributed to complete and prolong cytogenetic responses so that it is now the standard treatment of CML. Recently, Imatinib mesylate has shown...

Cite
Feki J, Marrekchi G, Boudawara T, et al. Subdural hematoma during therapy of gastro-intestinal stromal tumor (GIST) with Imatinib mesylate. Gulf J Oncolog. 2015;1(17):92-5
Feki, J., Marrekchi, G., Boudawara, T., Rekik, N., Maatouq, S., Boudawara, Z., & Frikha, M. (2015). Subdural hematoma during therapy of gastro-intestinal stromal tumor (GIST) with Imatinib mesylate. The Gulf journal of oncology, 1(17), 92-5.
Feki, J, et al. "Subdural hematoma during therapy of gastro-intestinal stromal tumor (GIST) with Imatinib mesylate." The Gulf journal of oncology vol. 1,17 (2015): 92-5.
Feki J, Marrekchi G, Boudawara T, Rekik N, Maatouq S, Boudawara Z, Frikha M. Subdural hematoma during therapy of gastro-intestinal stromal tumor (GIST) with Imatinib mesylate. Gulf J Oncolog. 2015 Jan;1(17):92-5. PMID: 25682460.
Copy Download .nbib Format: NLM
Complete remission of a periorbital dermatofibrosarcoma protuberans with adjuvant imatinib mesylate in a child.

JAAD case reports

Yen H, Pan SC, Huang CH, Wong TW.
PMID: 27051721
JAAD Case Rep. 2015 Jun 08;1(4):172-4. doi: 10.1016/j.jdcr.2015.04.003. eCollection 2015 Jul.

No abstract available.

Cite
Yen H, Pan SC, Huang CH, et al. Complete remission of a periorbital dermatofibrosarcoma protuberans with adjuvant imatinib mesylate in a child. JAAD Case Rep. 2015;1(4):172-4doi: 10.1016/j.jdcr.2015.04.003.
Yen, H., Pan, S. C., Huang, C. H., & Wong, T. W. (2015). Complete remission of a periorbital dermatofibrosarcoma protuberans with adjuvant imatinib mesylate in a child. JAAD case reports, 1(4), 172-4. https://doi.org/10.1016/j.jdcr.2015.04.003
Yen, Hsi, et al. "Complete remission of a periorbital dermatofibrosarcoma protuberans with adjuvant imatinib mesylate in a child." JAAD case reports vol. 1,4 (2015): 172-4. doi: https://doi.org/10.1016/j.jdcr.2015.04.003
Yen H, Pan SC, Huang CH, Wong TW. Complete remission of a periorbital dermatofibrosarcoma protuberans with adjuvant imatinib mesylate in a child. JAAD Case Rep. 2015 Jun 08;1(4):172-4. doi: 10.1016/j.jdcr.2015.04.003. eCollection 2015 Jul. PMID: 27051721; PMCID: PMC4808742.
Copy Download .nbib Format: NLM
Association of The Common CYP1A1*2C Variant (Ile462Val Polymorphism) with Chronic Myeloid Leukemia (CML) in Patients Undergoing Imatinib Therapy.

Cell journal

Lakkireddy S, Aula S, Avn S, Kapley A, Rao Digumarti R, Jamil K.
PMID: 26464823
Cell J. 2015;17(3):510-9. doi: 10.22074/cellj.2015.11. Epub 2015 Oct 07.

OBJECTIVE: Cytochrome P450 is one of the major drug metabolizing enzyme families and its role in metabolism of cancer drugs cannot be less emphasized. The association be- tween single nucleotide polymorphisms (SNPs) in CYP1A1 and pathogenesis of chronic myeloid...

Cite
Lakkireddy S, Aula S, Avn S, et al. Association of The Common CYP1A1*2C Variant (Ile462Val Polymorphism) with Chronic Myeloid Leukemia (CML) in Patients Undergoing Imatinib Therapy. Cell J. 2015;17(3):510-9doi: 10.22074/cellj.2015.11.
Lakkireddy, S., Aula, S., Avn, S., Kapley, A., Rao Digumarti, R., & Jamil, K. (2015). Association of The Common CYP1A1*2C Variant (Ile462Val Polymorphism) with Chronic Myeloid Leukemia (CML) in Patients Undergoing Imatinib Therapy. Cell journal, 17(3), 510-9. https://doi.org/10.22074/cellj.2015.11
Lakkireddy, Samyuktha, et al. "Association of The Common CYP1A1*2C Variant (Ile462Val Polymorphism) with Chronic Myeloid Leukemia (CML) in Patients Undergoing Imatinib Therapy." Cell journal vol. 17,3 (2015): 510-9. doi: https://doi.org/10.22074/cellj.2015.11
Lakkireddy S, Aula S, Avn S, Kapley A, Rao Digumarti R, Jamil K. Association of The Common CYP1A1*2C Variant (Ile462Val Polymorphism) with Chronic Myeloid Leukemia (CML) in Patients Undergoing Imatinib Therapy. Cell J. 2015;17(3):510-9. doi: 10.22074/cellj.2015.11. Epub 2015 Oct 07. PMID: 26464823; PMCID: PMC4601872.
Copy Download .nbib Format: NLM
Importance of early and deeper responses to long-term survival in CML patients: Implications of BCR-ABL testing in management of CML in Indian setting.

Indian journal of medical and paediatric oncology : official journal of Indian Society of Medical & Paediatric Oncology

Agarwal MB.
PMID: 25006277
Indian J Med Paediatr Oncol. 2014 Jan;35(1):10-6. doi: 10.4103/0971-5851.133704.

The prognosis of patients with chronic myeloid leukemia (CML) has changed radically since the advent of imatinib mesylate, a selective inhibitor of BCR-ABL tyrosine kinase. Shortly thereafter, more potent BCR-ABL inhibitors (dasatinib and nilotinib) were introduced for use in...

Cite
Agarwal MB. Importance of early and deeper responses to long-term survival in CML patients: Implications of BCR-ABL testing in management of CML in Indian setting. Indian J Med Paediatr Oncol. 2014;35(1):10-6doi: 10.4103/0971-5851.133704.
Agarwal, M. B. (2014). Importance of early and deeper responses to long-term survival in CML patients: Implications of BCR-ABL testing in management of CML in Indian setting. Indian journal of medical and paediatric oncology : official journal of Indian Society of Medical & Paediatric Oncology, 35(1), 10-6. https://doi.org/10.4103/0971-5851.133704
Agarwal, Mohan B. "Importance of early and deeper responses to long-term survival in CML patients: Implications of BCR-ABL testing in management of CML in Indian setting." Indian journal of medical and paediatric oncology : official journal of Indian Society of Medical & Paediatric Oncology vol. 35,1 (2014): 10-6. doi: https://doi.org/10.4103/0971-5851.133704
Agarwal MB. Importance of early and deeper responses to long-term survival in CML patients: Implications of BCR-ABL testing in management of CML in Indian setting. Indian J Med Paediatr Oncol. 2014 Jan;35(1):10-6. doi: 10.4103/0971-5851.133704. PMID: 25006277; PMCID: PMC4080644.
Copy Download .nbib Format: NLM
Incidence of BCR-ABL transcript variants in patients with chronic myeloid leukemia: Their correlation with presenting features, risk scores and response to treatment with imatinib mesylate.

Indian journal of medical and paediatric oncology : official journal of Indian Society of Medical & Paediatric Oncology

Deb P, Chakrabarti P, Chakrabarty S, Aich R, Nath U, Ray SS, Chaudhuri U.
PMID: 25006280
Indian J Med Paediatr Oncol. 2014 Jan;35(1):26-30. doi: 10.4103/0971-5851.133707.

CONTEXT: The exact role of the different transcript variants of BCR-ABL in the pathogenesis of chronic myeloid leukemia (CML) and their impact on prognosis is yet to be definitely enumerated.AIMS: In this study, we have tried to correlate the...

Cite
Deb P, Chakrabarti P, Chakrabarty S, et al. Incidence of BCR-ABL transcript variants in patients with chronic myeloid leukemia: Their correlation with presenting features, risk scores and response to treatment with imatinib mesylate. Indian J Med Paediatr Oncol. 2014;35(1):26-30doi: 10.4103/0971-5851.133707.
Deb, P., Chakrabarti, P., Chakrabarty, S., Aich, R., Nath, U., Ray, S. S., & Chaudhuri, U. (2014). Incidence of BCR-ABL transcript variants in patients with chronic myeloid leukemia: Their correlation with presenting features, risk scores and response to treatment with imatinib mesylate. Indian journal of medical and paediatric oncology : official journal of Indian Society of Medical & Paediatric Oncology, 35(1), 26-30. https://doi.org/10.4103/0971-5851.133707
Deb, Pratik, et al. "Incidence of BCR-ABL transcript variants in patients with chronic myeloid leukemia: Their correlation with presenting features, risk scores and response to treatment with imatinib mesylate." Indian journal of medical and paediatric oncology : official journal of Indian Society of Medical & Paediatric Oncology vol. 35,1 (2014): 26-30. doi: https://doi.org/10.4103/0971-5851.133707
Deb P, Chakrabarti P, Chakrabarty S, Aich R, Nath U, Ray SS, Chaudhuri U. Incidence of BCR-ABL transcript variants in patients with chronic myeloid leukemia: Their correlation with presenting features, risk scores and response to treatment with imatinib mesylate. Indian J Med Paediatr Oncol. 2014 Jan;35(1):26-30. doi: 10.4103/0971-5851.133707. PMID: 25006280; PMCID: PMC4080658.
Copy Download .nbib Format: NLM
Showing 1 to 12 of 448 entries